Previous Close | 40.34 |
Open | 39.10 |
Bid | 37.00 x 800 |
Ask | 36.94 x 1200 |
Day's Range | 36.20 - 39.15 |
52 Week Range | 31.01 - 50.21 |
Volume | |
Avg. Volume | 3,643,913 |
Market Cap | 18.8B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.15 |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | 1.16 (2.88%) |
Ex-Dividend Date | Feb 29, 2024 |
1y Target Est | 45.00 |
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
Robust Operational Performance Drives Growth Amidst Strategic Transformations